News Releases

GLI

August 26, 2016
GlycoBiomarker Leading Innovation Co. Ltd.

Receipt of the 14th Annual Merit Award from the Minister of Economy, Trade and Industry for Collaborative Achievement in Industry, Academia and Government


The 14th Minister of Economy, Trade and Industry (METI) Merit Award for the industry, academia, government collaboration achievement was given to our CTO and Prime Senior Researcher, Glycomedicine R&D Group, Dr. Atsushi Kuno (National Institute of Advanced Industrial Science and Technology [AIST] Chief senior researcher, Biotechnology Research Institute for Drug Discovery), AIST Principal research manager of Biotechnology Research Institute for Drug Discovery, Dr. Hisashi Narimatsu, and Executive vice president of Immunology & Chemistry Product Engineering Division, ICH Business Unit, Sysmex Corporation (Sysmex), Dr. Yoichi Takahama.


The Annual Merit Award for Industry, Academia and Government Collaborative Achievement was introduced in 2003 to recognize major success in industry–academia–government collaboration among companies, universities and public-sector research institutions successfully demonstrating substantial contribution through the promotion of leading-edge initiatives to help promote further industry–academia–government collaboration in Japan. The METI award is one of 12 awards bestowed from different ministries and agencies including the Prime Minister’s Award.


Overview of the 14th METI Annual Merit Award for Industry, Academia and Government Collaborative Achievement Theme

World’s first practical realization of a system for diagnosing hepatic fibrosis using glycosylation


Honorees

Hisashi Narimatsu (Principal Research Manager, Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology)
Atsushi Kuno (Chief Senior Researcher, Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology)
Yoichi Takahama (Executive Vice President, Immunology & Chemistry Product Engineering Division, ICH Business Unit, Sysmex Corporation)

Project summary

Intensive collaboration of the AIST, commercial company, and clinical institution network enabled rapid implementation of development, pharmaceutical approval, medical insurance coverage, and international distribution.

  • The system is the world’s first practical realization for diagnosing hepatic fibrosis using glycosylation. This clinical diagnostic system reduces the burden of about three millions of patients with chronic hepatitis, by such as reducing cost of clinical test compared with biopsy (some tens of thousands to 600 JPY/once with insurance coverage).
  • This diagnostic system enabled rapid (within 20 min) evaluation of fibrosis compared to several days taken with conventional approach. Without biopsy, the risk of breeding is reduced and frequent testing is possible, which realizes detailed observation of disease progression.
  • The system encourages appropriate selection of timing and dosage for hepatitis C drug, which costs about 6.5 million yen/patient, resulting in remarkable reduction of medical costs.
    (Summarized translation of METI website [Japanese])

Related Links

Cabinet Office website (Japanese)

Ministry of Economy, Trade and Industry website (Japanese)

Sysmex web site (Practical application)

Sysmex web site (Health insurance coverage)



Contact information

GlycoBiomarker Leading Innovation Co. Ltd. (GL-i)
1-1-1 Umezono, Tsukuba, Ibaraki 305-8568 Japan
E-mail: info@gl-i.co.jp / URL: http://www.gl-i.co.jp/


Page Top